Vaccine for cat allergies receives Phase II FDA approval

PURE Solutions NA, a developer of hypoallergenic technologies and products, announced on Monday that the U.S. Food and Drug Administration recently granted Phase II approval for a vaccine against cat allergies.

The vaccine, which is manufactured by U.K.-based Circassia, requires four shots over a 12-week period. Current cat allergy treatment methods require weekly injections over an eight month period, followed by injections at longer intervals. The FDA is currently undergoing Phase III tests on the drug and the vaccine could be approved as early as 2015.

When a cat cleans itself, allergenic proteins are released into the air and can easily escape to schools, vehicles and homes without cats. Circassia's vaccine produces synthetic versions of a part of the proteins in an attempt to switch off the specific cells that cause allergic reactions.

Steve Harris, the CEO of Circassia, said the effects of Circassia treatment can last for approximately a year.

"When patients were exposed to cat dander for three hours a day over four days, they had 'barely noticeable' symptoms," Harris said. "This suggests that they will be able to be in the same room and interact with cats."

Approximately 17 percent of the U.S. population is allergic to cats. Current treatments are considered tedious and have significant side effects.

PURE Solutions recommends prevention, including the use of hypoallergenic solutions, whether or not other treatments are available.